AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
1.42
+0.02 (1.43%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.35 - 1.44
52 week 0.61 - 3.50
Open 1.40
Vol / Avg. 957,551.00/2.20M
Mkt cap 79.12M
P/E     -
Div/yield     -
EPS -0.84
Shares 55.72M
Beta 0.90
Inst. own 33%
Sep 9, 2015
Aveo Pharmaceuticals Inc at FBR Healthcare Conference Add to calendar
Aug 10, 2015
Q2 2015 Aveo Pharmaceuticals Inc Earnings Call - Webcast
Aug 10, 2015
Q2 2015 Aveo Pharmaceuticals Inc Earnings Release
Jun 4, 2015
Aveo Pharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -4071.64% -291.01%
Operating margin -3448.51% -278.37%
EBITD margin - -179.34%
Return on average assets -52.29% -48.61%
Return on average equity -169.45% -116.49%
Employees 57 -
CDP Score - -

Address

One Broadway, 14Th Floor
CAMBRIDGE, MA 02142
United States - Map
+1-617-5312130 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company. The Company's platform has delivered insights into cancer and related disease. The Company's Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates. The Company's product candidates include AV203, Ficlatuzumab, Tivozanib and AV380. AV203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV380 is for treatment of cachexia. Tivozanib is a potent selective long halflife vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).

Officers and directors

Tuan Ha-Ngoc Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Michael P. Bailey President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Keith S. Ehrlich CPA Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Michael N. Needle M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Henri A. Termeer Lead Out Side Director
Age: 69
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 64
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Raju S. Kucherlapati Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert C. Young M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters